GPT and metabolic dysfunction-associated steatotic liver disease: Additional end points in earlier phase trials include noninvasive biomarkers (e.g., alanine transaminase [ALT], aspartate transaminase [AST]), MRI–proton density fat fraction (MRI-PDFF) for liver fat quantification, liver stiffness via elastography, and composite histology scores, such as the NAFLD activity score.